【発明の名称】酵素によって触媒される治療活性化

Japanese Patent JP2003505466

A

This invention provides novel substrate compounds that selectively inhibit the proliferation of pathological cells, for example, pathological cells that endogenously overexpress a target enzyme that confers resistance to biologic and chemotherapeutic agents. The enzyme acts on a substrate compound to 1) convert it to a cellular toxin and/or 2) release a toxic byproduct. In one embodiment, the activity of the target enzyme has been greatly enhanced in a target cell as a result of loss of tumor suppressor function and/or selection resulting from previous exposure to chemotherapy. In another embodiment, the pathological cell contains a target enzyme that is an expression product of an infectious agent in the cell. Further provided by this invention is a method for treating a subject by delivering to the subject a prodrug as described herein. The prodrugs of this invention may be used alone or in combination with other chemotherapeutics or alternative anti-cancer therapies such as radiation.

Shepherd, H. Michael
Chang, Min Phi
Grossack, Michael Pee.

JP2001512538A

February 12, 2003

July 21, 2000

Click for automatic bibliography generation  

New Biotics Incorporated

C12Q1/02; A61K31/7068; A61K31/7072; A61K47/48; A61P35/00; A61P43/00; C07F9/6512; C07H19/06; C07H19/073; C07H19/10; C07H19/23; C12Q1/527; (IPC1-7): C07H19/10; A61K31/7068; A61K31/7072; A61P35/00; A61P43/00; C07H19/073; C07H19/23; C12Q1/02; C12Q1/527

WO1999008110A1	1999-02-18
WO1999023104A2	1999-05-14
WO1999037753A1	1999-07-29
WO1999008110A1	1999-02-18
WO1999023104A2	1999-05-14
WO1999037753A1	1999-07-29

Shusaku Yamamoto

Previous Patent: 急性虚血により引き起こされる神経変性の処置において有用な三環式単糖�...

Next Patent: ＪＵＮＮ−末端キナーゼキナーゼ−１発現のアンチセンスモジュレーショ�...